Forecast Insight: Parkinson's Disease - Market Upgrade Following Evidence Of Disease Slowing With Az

By Author: Manjula Menon
Total Articles: 1486
Comment this article

Stimulated by evidence of disease slowing with Teva/Lundbeck's Azilect (rasagiline), and successful reformulation of leading dopamine agonists, the Parkinson's disease market value is set to grow by an compound annual growth rate (CAGR) of 10% over the next 5 years (20072013), peaking at $3.1 billion in 2013.

Scope of this report

This report gives a strategic analysis of the likely impact that recent events will have on the future Parkinson's disease market

Includes Parkinson's disease-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017

Provides a global market snapshot by including Parkinson's disease-specific sales analysis for leading brands outside the seven major markets

Key conclusions are supported by key opinion leader comment

Research and analysis highlights

It has upgraded its forecasts of Teva/Lundbeck's Azilect (rasagiline) following clinical evidence of disease slowing. Over the next 5 years Azilect is expected to become a standard first-line therapy, with sales peaking in 2013, making it the market leading Parkinson's ...
... disease drug at this time.

GlaxoSmithKline's Requip XL (ropinirole extended-release) is set to become the market leading dopamine agonist in 2009. The convenience of once-daily dosing, supported by the theoretical clinical advantage of smoother dopamine receptor agonism, will drive switching from the parent compound and Boehringer Ingelheim's Mirapex (pramipexole).

It has downgraded its sales forecasts of UCB's Neupro (rotigotine patch) as problems with crystallization of the active ingredient have led to supply issues at a critical phase in its lifecycle. Prescribers are now likely to switch to Requip XL, which arrived on the market at just the right time to take advantage of UCB's misfortune.

Key reasons to read this report

Understand the impact of recent and anticipated events on the Parkinson's disease market during the forecast period 2008 to 2017

Quantify the current size of the seven major markets and the trends in the rest of the world

Assess the impact of events, such as patent expiries and new product launches, on the Parkinson's disease-specific sales of key brands

For more information Kindly visit the website : http://www.bharatbook.com/detail.asp?id=83044

Or Contact us on :
Tel No : (+9122 )27578668 , 27579438
Fax: (+9122 )27579131

Address :
Bharat Book Bureau,
207,Hermes Atrium,
Sector-11
P.O Box 54,
CBD Belapur,
Navi Mumbai - 400614.

Stimulated by evidence of disease slowing with Teva/Lundbeck's Azilect (rasagiline), and successful reformulation of leading dopamine agonists, the Parkinson's disease market value is set to grow by an compound annual growth rate (CAGR) of 10% over the next 5 years (20072013), peaking at $3.1 billion in 2013.

Scope of this report

This report gives a strategic analysis of the likely impact that recent events will have on the future Parkinson's disease market

Includes Parkinson's disease-specific sales forecasts for the key brands and pipeline agents in the seven major markets to 2017

Provides a global market snapshot by including Parkinson's disease-specific sales analysis for leading brands outside the seven major markets

Key conclusions are supported by key opinion leader comment

Research and analysis highlights

It has upgraded its forecasts of Teva/Lundbeck's Azilect (rasagiline) following clinical evidence of disease slowing. Over the next 5 years Azilect is expected to become a standard first-line therapy, with sales peaking in 2013, making it the market leading Parkinson's disease drug at this time.

GlaxoSmithKline's Requip XL (ropinirole extended-release) is set to become the market leading dopamine agonist in 2009. The convenience of once-daily dosing, supported by the theoretical clinical advantage of smoother dopamine receptor agonism, will drive switching from the parent compound and Boehringer Ingelheim's Mirapex (pramipexole).

It has downgraded its sales forecasts of UCB's Neupro (rotigotine patch) as problems with crystallization of the active ingredient have led to supply issues at a critical phase in its lifecycle. Prescribers are now likely to switch to Requip XL, which arrived on the market at just the right time to take advantage of UCB's misfortune.

Key reasons to read this report

Understand the impact of recent and anticipated events on the Parkinson's disease market during the forecast period 2008 to 2017

Quantify the current size of the seven major markets and the trends in the rest of the world

Assess the impact of events, such as patent expiries and new product launches, on the Parkinson's disease-specific sales of key brands

For more information Kindly visit the website : http://www.bharatbook.com/detail.asp?id=83044

Or Contact us on :
Tel No : (+9122 )27578668 , 27579438
Fax: (+9122 )27579131

Address :
Bharat Book Bureau,
207,Hermes Atrium,
Sector-11
P.O Box 54,
CBD Belapur,
Navi Mumbai - 400614.

Bharat Book Bureau is the leading market research information aggregator which provides reports, company profiles, newsletters, country info. and online databases for the past twenty years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Bharat Book Bureau provides strategic information tools to the executives, business analysts, and knowledge managers that will help them to probe into and support critical, timely business decisions and strategies.It helps global companies to know different market before starting up business / expanding in different countries across the world. www.bharatbook.com is one stop shop for the business intelligence information requirements.